NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024.
Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&P 500 also rose, gaining, 0.87% to 4,887.70.